Compare MEOH & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEOH | ICUI |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | MEOH | ICUI |
|---|---|---|
| Price | $48.67 | $154.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $48.11 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 512.4K | 209.2K |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 40.35 | N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $3,569,374,000.00 | $2,320,363,000.00 |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $12.55 | N/A |
| P/E Ratio | $16.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.46 | $107.00 |
| 52 Week High | $54.49 | $175.51 |
| Indicator | MEOH | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 57.90 |
| Support Level | $44.78 | $152.38 |
| Resistance Level | $49.36 | $160.29 |
| Average True Range (ATR) | 1.57 | 5.13 |
| MACD | 0.17 | 0.43 |
| Stochastic Oscillator | 90.80 | 75.33 |
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.